Prestige Consumer Healthcare presents a mixed fundamental picture: a resilient, asset-light consumer health portfolio generates robust cash flows (cumulative OCF exceeded net income by 34% over ten quarters), yet recent quarters reveal persistent top-line pressure and margin compression, with 2027Q1 gross margin down…
Price trend, volume and key moving averages
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $1.13+5.6% vs $1.07 | $336M+2.2% vs $329M |
Q3 2026 Aug 6, 2026 | $0.98+9.6% vs $0.89 | $266M+5.0% vs $253M |
Q2 2026 May 13, 2026 | $1.23-11.5% vs $1.39 | $282M-4.1% vs $294M |
Q1 2026 Feb 5, 2026 | $1.14-1.7% vs $1.16 | $283M+0.4% vs $282M |
Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
TARRYTOWN, N.Y., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first half fiscal 2027 ended September 30, 2026.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts.
During the third quarter of 2026, the Small Cap strategy slightly underperformed its benchmark, the Russell 2000 Index, in a period in which small cap stocks broadly declined. Top contributors include AtriCure and Red Violet; top detractors include Kodiak Gas Services and PDF Solutions. We initiated a position in IRadimed at the start of the quarter, replacing Talkspace after it was acquired.
Benchmark PBH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Prestige Consumer Healthcare Inc. (PBH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $42.98 | $2.04B | 13.19 | -4.31% | 13.29% | 8.19% | — | |
| $86.68 | $2.01B | 25.12 | -5.23% | 2.77% | 4.18% | 2.15% | |
| $109.33 | $25.91B | 33.68 | 1.57% | 12.41% | 18.21% | 1.08% | |
| $23.84 | $1.63B | 20.24 | 2.28% | 2.73% | 47.41% | 5.07% | |
| $15.85 | $2.19B | -1.25 | -2.75% | -43.27% | -68.13% | 7.26% | |
| $4.05 | $3.57B | -6.35 | -1.46% | -9.74% | -16.47% | 0.37% |
Prestige Consumer Healthcare Inc. (PBH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Prestige Consumer Healthcare Inc. (PBH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Aug 6, 2026·SEC
Jul 15, 2026·SEC
Get notified when PBH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Prestige Consumer Healthcare Inc. (PBH) stock FAQ — growth, dividends, profitability & financials explained
Prestige Consumer Healthcare Inc. (PBH) reported $1.17B in revenue over the trailing twelve months. Revenue was $1.09B in fiscal year 2026. That is 12479% more than the $8.7M of fiscal year 2001.
Prestige Consumer Healthcare Inc. (PBH) grew revenue by 5.1% over the trailing twelve months, compared with the twelve months before.
Yes. Prestige Consumer Healthcare Inc. (PBH) earned $155.1M in net income over the trailing twelve months (a 13.3% net margin).
Prestige Consumer Healthcare Inc. (PBH) had a return on equity (ROE) of 8.2% over the trailing twelve months. That is below the market's typical 10-15%.
Prestige Consumer Healthcare Inc. (PBH) generated $214.2M in free cash flow over the trailing twelve months.
